InFlectis BioScience Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.77M

  • Investors
  • 7

InFlectis BioScience General Information

Description

Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclinical-stage development products that modulate key proteins involved in misfolded protein disorders areas through early proof-of-concept, enabling clients to maximize the commercial value of each of its products, improve patient care and generate significant financial returns for shareholders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 21 rue La Noue Bras de Fer
  • 44200 Nantes
  • France
+33 02 00 00 00 00

InFlectis BioScience Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InFlectis BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 27-Jan-2023 $3.77M 000.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 31-Dec-2021 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 27-May-2016 00.00 00.000 000.00 Completed Clinical Trials - Phase 2
2. Seed Round 13-Jan-2015 $2.11M $2.11M Completed Clinical Trials - Phase 2
1. Grant 01-Jan-2014 $411K Completed Clinical Trials - Phase 2
To view InFlectis BioScience’s complete valuation and funding history, request access »

InFlectis BioScience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference P5 00,000 00.000000 000.00 000.00 00 000.00 00.000
Class O 0,000 00.000000 000.00 000.00 000.00 0.000
Preference P3 0,000 00.000000 000.00 000.00 00 000.00 0.000
Preference P3 0,000 00.000000 000.0 000.0 00 000.0 0.000
Preference P3 0,000 00.000000 000.00 000.00 00 000.00 0.000
Preference P3 000 00.000000 000.00 000.00 00 000.00 0.00
Preference P3 000 00.000000 000.0 000.0 00 000.0 0.00
Preference P3 000 00.000000 000.00 000.00 00 000.00 0.00
Preference P3 25,502 $1.075925 $70.06 $70.06 1x $70.06 7.31%
Preference P3 25,478 $1.075925 $70.12 $70.12 1x $70.12 7.3%
To view InFlectis BioScience’s complete cap table history, request access »

InFlectis BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclini
Drug Discovery
Nantes, France
9 As of 2023
000.00
000.00 0000-00-00
0000000000 0 000.00

000 00

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pa
0000000000000
Elstree, United Kingdom
0000 As of 0000
000000000000

00000

sum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididun
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InFlectis BioScience Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bio Products Laboratory Private Equity-Backed Elstree, United Kingdom 0000 000000000000
Verge Genomics Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 0 00000
Calico Venture Capital-Backed San Francisco, CA 000 000 000000000 000
Cerecin Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
ImmunityBio Formerly VC-backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 57 competitors. Get the full list »

InFlectis BioScience Patents

InFlectis BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3328369-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Pending 31-Jul-2015 0000000000
US-10675257-B2 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Active 31-Jul-2015 0000000000 0
US-20180221310-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Active 31-Jul-2015 0000000000
AU-2016304331-B2 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. Inactive 31-Jul-2015 0000000000 0
AU-2016304331-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. Active 31-Jul-2015 A61K31/155
To view InFlectis BioScience’s complete patent history, request access »

InFlectis BioScience Executive Team (5)

Name Title Board Seat Contact Info
Pierre Miniou Ph.D Co-Founder, President & Chief Executive Officer
Philippe Jaffré Chief Financial Officer
Beatrice Lejeune Chief Regulatory Officer
Philippe Guedat Ph.D Co-Founder
Anne Visbecq MD Chief Medical Officer
To view InFlectis BioScience’s complete executive team members history, request access »

InFlectis BioScience Board Members (4)

Name Representing Role Since
Jérôme Guéret GO Capital (France) Board Member 000 0000
Taro Inaba Remiges Ventures Board Member 000 0000
You’re viewing 2 of 4 board members. Get the full list »

InFlectis BioScience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InFlectis BioScience Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Crédit Mutuel Innovation Venture Capital Minority 000 0000 000000 0
Crédit Mutuel Equity Growth/Expansion Minority 000 0000 000000 0
Remiges Ventures Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
GO Capital (France) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

InFlectis BioScience FAQs

  • When was InFlectis BioScience founded?

    InFlectis BioScience was founded in 2013.

  • Who is the founder of InFlectis BioScience?

    Pierre Miniou Ph.D and Philippe Guedat Ph.D are the founders of InFlectis BioScience.

  • Who is the CEO of InFlectis BioScience?

    Pierre Miniou Ph.D is the CEO of InFlectis BioScience.

  • Where is InFlectis BioScience headquartered?

    InFlectis BioScience is headquartered in Nantes, France.

  • What is the size of InFlectis BioScience?

    InFlectis BioScience has 9 total employees.

  • What industry is InFlectis BioScience in?

    InFlectis BioScience’s primary industry is Drug Discovery.

  • Is InFlectis BioScience a private or public company?

    InFlectis BioScience is a Private company.

  • What is the current valuation of InFlectis BioScience?

    The current valuation of InFlectis BioScience is 000.00.

  • What is InFlectis BioScience’s current revenue?

    The current revenue for InFlectis BioScience is 000000.

  • How much funding has InFlectis BioScience raised over time?

    InFlectis BioScience has raised $46.6M.

  • Who are InFlectis BioScience’s investors?

    Crédit Mutuel Innovation, Crédit Mutuel Equity, Remiges Ventures, Bpifrance, and GO Capital (France) are 5 of 7 investors who have invested in InFlectis BioScience.

  • Who are InFlectis BioScience’s competitors?

    Bio Products Laboratory, Verge Genomics, Calico, Cerecin, and ImmunityBio are some of the 57 competitors of InFlectis BioScience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »